Effectively Introducing a New Meningococcal A Conjugate Vaccine in Africa: The Burkina Faso Experience
In 2010, Burkina Faso conducted a country-wide campaign to introduce a new Group A meningococcal conjugate vaccine, MenAfriVac™. Leading up to this effort, the following challenges were successfully managed: (1) conducting a large safety study and registering the new vaccine in Burkina Faso; (2) developing a comprehensive communication plan; (3) strengthening the surveillance system with particular attention to improving the capacity for real-time polymerase chain reaction testing of spinal fluid specimens; (4) improving cold chain capacity and waste disposal; (5) developing and funding a sound campaign strategy; and (6) ensuring effective collaboration across all partners. This article, published in Vaccine, discusses each of these challenges and demonstrates that African national immunization programs are capable of achieving high coverage for a vaccine desired by the public, introduced in a well-organized campaign, and supported at the highest political level. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Djingarey MH, Barry R, Bonkoungou M, et al.
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Djingarey MH, Barry R, Bonkoungou M, et al. Effectively Introducing a New Meningococcal A Conjugate Vaccine in Africa: The Burkina Faso Experience. Vaccine. 2012;30(S2):B40-B45.